CLINICAL TRIAL SUMMARY

MDACC Study No:2012-1003 (clinicaltrials.gov NCT No: NCT01950351)
Title:Phase II Trial of hypofractionated proton beam therapy in men with localized prostate adenocarcinoma
Principal Investigator:Thomas Pugh
Treatment Agent:Proton Therapy
Study Status:Open
Study Description:The goal of this clinical research study is to learn if delivering proton
therapy in higher doses per treatment may help control prostate cancer just as
well as the standard of care treatment. The safety of this treatment will also
be studied.

Radiation dose is measured in units called Gray (Gy). The standard of care
treatment schedule for proton therapy is 1.8-2 Gy, given 1 time per day, 5 days
per week over a period of 8-9 weeks.

Hide details for General InformationGeneral Information

Disease Group:Genitourinary
Phase of Study:Phase II
Treatment Agents:Proton Therapy
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Cher and John Floyd Prostate Cancer Research Fund
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Thomas Pugh
Dept:Radiation Oncology
For Clinical Trial Enrollment:713-563-8961
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults